Study summary

Tumor-treating fields with immunotherapy delayed growth in a small trial

TTFields plus pembrolizumab trial · 31 people, phase 2 · Published June 2025, Med

What was tested

Tumor-treating fields (a wearable device sending electric fields through the scalp) plus pembrolizumab and temozolomide after standard chemoradiation, compared with matched past patients.

What they found

• Median time before growth was 12.0 months vs 5.8 in matched controls.
• The device appeared to prime T cells that immunotherapy then sustained.

What it means

Promising enough for a 741-person phase 3 (EF-41), now fully enrolled.